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ABSTRACT
Purpose To describe the characteristics of new users of cilostazol in Europe with the aim to support the evaluation of its beneﬁt/risk as
used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency.
Methods New users of cilostazol were identiﬁed in populations enrolled in ﬁve European health automated databases in the UK (The
Health Improvement Network [THIN]), Spain (EpiChron cohort and Information System for the Improvement of Research in Primary Care
[SIDIAP]), Sweden (National Registers), and Germany (German Pharmacoepidemiological Research Database [GePaRD]) between 2002
and 2012. New users were characterized according to the prevalence of cardiovascular disease and other comorbidities, concurrent use of
interacting medications, new contraindications, duration of use, and potential off-label prescribing.
Results We identiﬁed 22 593 new users of cilostazol. The median age was between 68.0 (THIN) and 73.7 (Sweden) years. More than 78%
of users had concomitant cardiovascular disease, and between 78.8% (GePaRD) and 91.6% (THIN) were treated with interacting
medications. Prevalence of new cardiovascular contraindications ranged from 1.5% (THIN) to 11.6% (GePaRD), and concurrent use of
two or more antiplatelet drugs ranged from 6.3% (SIDIAP) to 13.5% (EpiChron cohort). Between 39.4% (Sweden) and 52.9% (THIN) of
users discontinued cilostazol in the ﬁrst 3 months. Between 41.0% (SIDIAP) and 93.4% (THIN) were considered to have received cilostazol
according to the European Medicines Agency labeling.
Conclusions In this collaborative European study, most cilostazol users were elderly patients with a high prevalence of cardiovascular diseases
and other comorbidity and concurrent use of interacting drugs, indicating that this is a vulnerable population at high risk of complications,
especially cardiovascular events. © 2017 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
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INTRODUCTION
Cilostazol is a platelet aggregation inhibitor approved
in Europe in 2002 to improve walking distances in
patients with intermittent claudication. Cilostazol has
been associated with spontaneous reports of car-
diovascular adverse effects (heart attacks, angina, and
arrhythmias) and serious bleeding. The European
Medicines Agency (EMA) evaluated the beneﬁts and
risks of cilostazol in a referral and recommended
labeling changes to include contraindications to
patients with unstable angina pectoris, recent myocar-
dial infarction, or recent coronary intervention
(Table 1).1 The EMA also required a drug utilization
study to support the beneﬁt–risk evaluation of
cilostazol before the implementation of labeling
changes, which were introduced in 2013.
We present results of the drug utilization study
conducted in the UK, Spain, Sweden, and Germany
by using information from automated health
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databases. The main objectives were to describe the
characteristics of new users of cilostazol, including
comorbidity and comedications, to assess potential
off-label prescribing and conduct a baseline assess-
ment of the labeling changes recommended by the
EMA.
METHODS
Data sources
New users of cilostazol were identiﬁed in ﬁve
databases: The Health Improvement Network (THIN),
UK2–4; the EpiChron cohort from Aragon Health
Sciences Institute, Aragon, Spain; the Information
System for the Improvement of Research in Primary
Care (SIDIAP), Catalonia, Spain5; the Swedish
National Registers6,7; and the German Pharma-
coepidemiological Research Database (GePaRD).8
Main characteristics of the study databases are
presented in Table S1.
Study population
The study included all new users of cilostazol
identiﬁed in the study databases because the date
cilostazol was available in each country before the
implementation in 2013 of labeling changes requested
by the EMA. New users were deﬁned as patients who
received a ﬁrst-ever prescription of cilostazol during
the study period and had at least 6 months of continu-
ous enrollment in the study databases before this ﬁrst
prescription (start date). New users were followed
from the start date until the earliest of end of enroll-
ment in the database, death, or end of the study period.
Exposure deﬁnition
We deﬁned exposure to cilostazol as the number of
days’ supply calculated from the quantity prescribed
and dosage instructions or from a descriptive analysis
of the time between consecutive prescriptions. An
interval of 7 days was added to days’ supply to allow
for delay in the start of treatment and incomplete
adherence. Continuous use of cilostazol was deﬁned
as the total number of days covered by consecutive
prescriptions, with a maximum gap of 60 days
between the end of days’ supply of one prescription
and the start of the next prescription. In THIN and
the EpiChron cohort, daily dose was calculated from
strength of product, package quantity, and dosage
instructions. In the EpiChron cohort, daily dose infor-
mation was available for 1052 patients (26.1%). In
Sweden and GePaRD, daily dose was calculated by
assuming a twice-daily dosage. In SIDIAP, evaluation
of daily dose was not conducted as information on
dosage instructions was not available.
Characterization of users
New users of cilostazol were characterized at the start
date according to age, sex, socioeconomic status,
comorbidity and comedications, concurrent use of
interacting medications, and contraindications before
and after the EMA-requested labeling changes.
Interacting medications evaluated were those
interacting with cytochrome P-450 (CYP) enzymes,
particularly CYP3A4 and CYP2C19, including potent
CYP3A4 and CYP2C19 inhibitors.9,10
Old cilostazol contraindications evaluated were
severe renal impairment, moderate-to-severe hepatic
impairment, congestive heart failure, predisposing
factors for bleeding (active peptic ulcer, hemorrhagic
stroke within the prior 6 months, proliferative diabetic
retinopathy, and poorly controlled hypertension), and
history of speciﬁc arrhythmia.
Baseline assessment of labeling changes
To assess the potential impact of the cilostazol labeling
changes, we conducted a baseline assessment of the
frequency of conditions included in the labeling
recommended by the EMA (Table 1). Information on
smoking was available in THIN, the EpiChron cohort,
and SIDIAP. In Sweden, we evaluated smoking by
using diagnosis codes for smoking-related disease
Table 1. Changes to the cilostazol summary of product characteristics,
2013
Indication
Second-line use after lifestyle modiﬁcations,
including smoking cessation and (supervised)
exercise programmes, failed to
sufﬁciently improve symptoms.
Physician reassessment of patients after 3
months of treatment with a view to
discontinuing cilostazol where an
inadequate effect is observed
Contraindications Unstable angina pectoris, myocardial infarction
within the last 6 months, or a coronary
intervention in the last 6 months
Concomitant treatment with two or more
additional antiplatelet agents (e.g., aspirin and
clopidogrel)
Warnings and
precautions
Close monitoring of patients at increased risk
for serious cardiac adverse events as a result
of increased heart rate, for example,
patients with stable coronary disease or a
history of tachyarrhythmias
Posology Reduction of the dose to 50 mg twice daily
in patients receiving medicines that strongly
inhibit CYP3A4 or CYP2C19
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and use of smoking-cessation drugs. Information on
smoking was not available in GePaRD. Monitoring
of patients after 3 months was assessed by the number
of patients who had at least one visit to a general prac-
titioner (GP) or specialist (vascular surgery, cardiol-
ogy, and diabetology) 2–4 months after the start date.
In Sweden, evaluation of visits was restricted to the
hospital setting. In GePaRD, diagnoses are recorded
on a quarterly basis and visits were evaluated by the
number of patients who had at least one diagnosis for
intermittent claudication recorded in the 3 months
following the quarter in which cilostazol was started.
In THIN and SIDIAP, the reason for visits to GPs
and specialists was assessed by clinically reviewing
computerized information and free text for a random
sample of 200 patients. Discontinuation of cilostazol
after 3 months was evaluated for the ﬁrst period of
continuous use. New contraindications included in
the revised label approved by the EMA were unstable
angina pectoris, myocardial infarction or coronary
intervention within 6 months before the start date,
and concurrent use of cilostazol and two or more addi-
tional platelet aggregation inhibitors. Monitoring of
patients at increased risk of serious cardiac events
was evaluated by comparing rates of visits to GPs or
specialists between patients with and without a history
of arrhythmias, hypotension, or coronary heart
disease. In GePaRD, monitoring was expressed as
the number of diagnoses per patient-year of
continuous use because only the ﬁrst visit to the same
physician is recorded during a quarter.
Potential off-label prescribing
In THIN and SIDIAP, potential off-label prescribing
was evaluated through manual review of computer-
ized clinical information and free text of a random
sample of 200 patients. In other databases, indication
was evaluated by using diagnostic codes and
referrals. On-label prescribing was deﬁned as any
patient who had a recorded diagnosis of intermittent
claudication or peripheral arterial disease recorded
at any time before or after the start date or who
had a referral to vascular surgery, cardiology, or
diabetology within 1 month before and 1 month after
the start date (28 days were used in Germany). In
Germany, the period of ascertainment of diagnoses
was the calendar quarter before and after the start
date.
Analysis
The average annual prevalence of cilostazol use was
calculated by using the age and sex distribution of
the population in each database. The cumulative
proportion of patients discontinuing cilostazol was
calculated by using survival analysis. Rates of visits
were calculated as the number of visits per
100 person-years of continuous use of cilostazol,
except in GePaRD, where the number of diagnoses
per patient-year was used. Crude incidence rate ratios
and 95% conﬁdence intervals were estimated to
compare rates of visits between patients at high risk
of cardiac complications and patients not at high risk.
At RTI Health Solutions (RTI-HS; THIN data),
SIDIAP, Sweden, and GePaRD, analyses were
conducted by using SAS version 9.3 or 9.4 (Cary,
NC: SAS Institute Inc.). STATA v13.0 (StataCorp,
2013) was used in the EpiChron cohort. STATA v13.1
and R 3.1 (R Core Team, 2013) were also used in
SIDIAP.
The protocol was approved by the EMA and posted
in the EU PAS Register in March 2013 (EU PAS ID
3596).11
RESULTS
Prevalence and patterns of use
We included 22 593 new users of cilostazol. SIDIAP
(Spain) contributed the largest proportion of users
(44.9%; Table 2). The average annual prevalence of
cilostazol use was higher in Spain than in the other
countries. Between 52.3% (Sweden) and 77.3%
(SIDIAP) of users were men. The median age ranged
from 68.0 years in SIDIAP to 73.7 years in Sweden
and was higher in women than in men in all study
populations.
From 15.9% (SIDIAP) to 42.0% (Sweden) of users
received only one prescription. Most users received a
daily dose of 200 mg at the start date. The
percentage of users discontinuing cilostazol in the
ﬁrst 6 months of treatment ranged from 50.4% in
SIDIAP to 65.2% in Sweden. Information on
socioeconomic status of new users of cilostazol is
presented in Table S2.
Baseline comorbidity
Cardiovascular disease other than peripheral vascular
disease was the most frequent comorbidity in all study
populations, affecting 62.8% (Sweden) to 95.7%
(GePaRD) of users (Table 3). The most frequent
cardiovascular condition was hypertension, ranging
from 46.8% (Sweden) to 86.0% of users (GePaRD).
Between 20.4% (Sweden) and 75.3% (GePaRD) of
users had a recorded diagnosis of hyperlipidemia,
and 20.5% (Sweden) to 41.1% (GePaRD) had a
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diagnosis of diabetes. Use of comedications at the start
date was consistent with the prevalence of comorbidity
(Table S3). The most frequent comedications were
antihypertensive drugs (63.6 to 80.6% of users),
platelet aggregation inhibitors (33.8 to 73.1%), lipid-
modifying agents (45.8 to 68.6%), and proton pump
inhibitors (22.4 to 60.9%).
Concurrent use of interacting medications
Between 78.8% (GePaRD) and 91.6% (THIN) of
users were concurrently treated with interacting
medications (Table S4). The most frequent interacting
medications were simvastatin, atorvastatin,
amlodipine, omeprazole, and clopidogrel. The per-
centages of users treated with potent CYP3A4 or
CYP2C19 inhibitors were 2.7% (Sweden), 3.8%
(GePaRD), 7.3% (SIDIAP), 10.2% (EpiChron co-
hort), and 22.3% (THIN). Between 26.9% (GePaRD)
and 69.0% (THIN) of users were concurrently treated
with other platelet aggregation inhibitors. Among
these users, 8.5% (SIDIAP) to 21.1% (GePaRD)
discontinued platelet aggregation inhibitors after
starting cilostazol.
Assessment of contraindications
The percentages of users with diagnoses suggestive of
contraindications included in the label before the 2013
changes were 6.2% (EpiChron cohort), 10.0% (THIN),
12.2% (Sweden), 39.1% (SIDIAP), and 51.8%
(GePaRD; Table 4). The prevalence of each individual
contraindication, except heart failure, was higher in
GePaRD than in other study populations. SIDIAP
was the only database in which poorly controlled
hypertension could be evaluated.
Baseline assessment of labeling changes
The baseline assessment of labeling changes is
presented in Table 5. For databases with information
from GPs, current smoking at the start date was found
in 15.9% of users (EpiChron cohort), 30.4% (THIN),
and 32.3% (SIDIAP). In these populations,
80.9–83.6% of users had a visit with a GP or
specialist 2–4 months after starting cilostazol.
Discontinuation within the ﬁrst 3 months ranged from
39.4% (Sweden) to 52.9% (THIN) of users. Between
1.5% (THIN) and 11.6% (GePaRD) of users had new
cardiovascular contraindications at the start date, and
Table 2. Study period, number of new users, age and sex distribution, and patterns of use of cilostazol
Characteristic THIN, UK
EpiChron Cohort,
Aragon, Spain
SIDIAP, Catalonia,
Spain Sweden
GePaRD,
Germany
Study period 29 Jul 2002–14
Sep 2012
1 Jun 2009–31
Dec 2012
1 Jun 2009–31
Dec 2012
1 Jan 2008–31
Dec 2012
1 Jan 2007–31
Dec 2011
Number of users 1528 4024 10 142 2887 4012
Average annual prevalence
of use (per 100 000)
8.9 162.4 133.5 13.3 17.0
Men 65.6% 72.2% 77.3% 52.3% 73.3%
Median age (years)
Men 68.0 69.0 68.0 72.4 67.8
Women 71.0 73.9 75.0 75.0 68.7
Total number of prescriptions 21 513 35 719 47 205 11 295 23 478
Total number of DDDs 715 716 1 133 944 3 738 812 613 897 982 846
Total number of prescriptions
per user
1 28.6% 31.1% 15.9% 42.0% 32.9%
2–4 22.8% 20.4% 18.9% 29.2% 28.9%
5+ 48.6% 48.5% 65.2% 28.8% 38.2%
Number of users of 50-mg strength 25.8% NA* NA* 23.4% 14.5%
Number of users of 10-mg strength 82.1% 100% 100% 81.0% 91.7%
Daily dose of 200 mg at start date 85.7% 77.3% NA** 78.1% 87.9%
Discontinuation of use
<1 month 28.7% 33.9% 22.2% 38.2%*** –
<3 months 52.9% 51.9% 40.6% 39.4% 51.9%
<6 months 62.2% 60.5% 50.4% 65.2% 64.9%
<12 months 71.3% 69.1% 64.6% 81.9% 77.8%
<24 months 79.8% 77.8% 82.0% 92.1% 87.5%
GePaRD, German Pharmacoepidemiological Research Database, Germany; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS),
Aragón, Spain; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network,
UK; UK, United Kingdom.
*Strength of 50 mg was not available in Spain.
**Information on daily dose not available in SIDIAP.
***Refers to ﬁrst 2 months of treatment.
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6.3% (SIDIAP) to 13.5% (EpiChron cohort) were
concurrently treated with two or more additional plate-
let aggregation inhibitors. In all databases, rates of
visits with GPs or specialists were higher in users with
increased risk of serious cardiovascular events than in
users without such risk. Between 2.1% (Sweden) and
19.6% (THIN) of users had concurrent use of
cilostazol 200 mg per day and potent CYP3A4 or
CYP2C19 inhibitors. Among patients treated with a
daily dose of 200 mg who started potent inhibitors
during follow-up (n = 235), reduction of the cilostazol
daily dose was found in one patient.
Off-label prescribing
Between 41.0% (SIDIAP) and 93.4% (THIN) of users
had a recorded diagnosis compatible with the labelled
indication (Table 6). Potential off-label prescribing
ranged from 5.6% (THIN) to 24.5% (Sweden) of
users. Between 1.0% (THIN) and 48.7% (SIDIAP) of
users had recorded diagnoses not related to the
potential on-label use of cilostazol or did not have
any recorded diagnosis around the start date. Potential
off-label cardiovascular indications of cilostazol were
cerebrovascular disease (0.3%, EpiChron cohort and
Table 3. Comorbidity among new users of cilostazol*
Disease description THIN, UK
EpiChron Cohort,
Aragon, Spain
SIDIAP, Catalonia,
Spain Sweden
GePaRD,
Germany
(n = 1528) (n = 4024) (n = 10 142) (n = 2887) (n = 4012)
n % n % n % n % n %
Cardiovascular diseases and procedures 1399 91.6 3251 80.8 9027 89.0 2290 79.3 3972 99.0
Diseases of arteries, arterioles,
and capillaries
1101 72.1 1453 36.1 5097 50.3 1605 55.6 3690 92.0
Intermittent claudication 808 52.9 1453 36.1 4268 42.1 1043 36.1 3151 78.5
Other peripheral arterial disease 652 42.7 1453 36.1 499 4.9 1003 34.7 3149 78.5
Revascularization procedures 164 10.7 0 0.0 4 0.0 525 18.2 1349 33.6
Cardiovascular disease excluding diseases
of arteries, arterioles, and capillaries
1157 75.7 2997 74.5 8338 82.2 1812 62.8 3838 95.7
Ischemic heart disease 497 32.5 563 14.0 1746 17.2 912 31.6 2111 52.6
Acute myocardial infarction 194 12.7 274 6.8 674 6.6 399 13.8 631 15.7
Unstable angina pectoris 60 3.9 229 5.7 114 1.1 264 9.1 408 10.2
Angina pectoris 301 19.7 229 5.7 161 1.6 609 21.1 750 18.7
Coronary reperfusion and procedures 189 12.4 0 0.0 48 0.5 531 18.4 518 12.9
Arrhythmias 138 9.0 157 3.9 629 6.2 338 11.7 1199 29.9
Paroxysmal tachycardia 6 0.4 9 0.2 47 0.5 47 1.6 167 4.2
Atrial ﬁbrillation and ﬂutter 97 6.3 133 3.3 475 4.7 260 9.0 535 13.3
Heart failure 73 4.8 118 2.9 406 4.0 266 9.2 983 24.5
Cerebrovascular disease 189 12.4 313 7.8 971 9.6 339 11.7 1815 45.2
Hypertension 825 54.0 2209 54.9 6388 63.0 1352 46.8 3451 86.0
Hypotension 37 2.4 14 0.4 27 0.3 25 0.9 264 6.6
Disorders of lipoprotein metabolism 478 31.3 1503 37.4 4915 48.5 589 20.4 3021 75.3
Bleeding disorders 346 22.6 160 4.0 568 5.6 338 11.7 1120 27.9
Cerebral hemorrhage 8 0.5 0 0.0 30 0.3 20 0.7 62 1.5
Gastrointestinal bleeding 169 11.1 44 1.1 230 2.3 142 4.9 504 12.6
Gastroduodenal bleeding 61 4.0 18 0.5 94 0.9 102 3.5 299 7.5
Lower gastrointestinal bleeding 114 7.5 26 0.7 135 1.3 38 1.3 190 4.7
Genitourinary 133 8.7 87 2.2 213 2.1 122 4.2 451 11.2
Other site 90 5.9 33 0.8 152 1.5 77 2.7 276 6.9
Blood dyscrasias 97 6.3 203 5.0 378 3.7 162 5.6 923 23.0
Peptic ulcer disease 136 8.9 83 2.1 549 5.4 101 3.5 354 8.8
Liver disease 20 1.3 63 1.6 396 3.9 30 1.0 1021 25.4
Renal failure 37 2.4 0 0.0 830 8.2 80 2.8 830 20.7
Skin disorders 399 26.1 641 15.9 882 8.7 225 7.8 1691 42.1
Diabetes mellitus 326 21.3 1201 29.9 4102 40.4 593 20.5 1648 41.1
Chronic obstructive pulmonary disease 194 12.7 694 17.3 1823 18.0 247 8.6 1727 43.0
Asthma 215 14.1 115 2.9 206 2.0 106 3.7 395 9.8
Rheumatoid arthritis 30 2.0 198 4.9 666 6.6 144 5.0 921 23.0
Malignancy 197 12.9 316 7.9 1107 10.9 481 16.7 1002 25.0
COPD, chronic obstructive pulmonary disease; GePaRD, German Pharmacoepidemiological Research Database, Germany; GP, general practitioner;
EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS), Aragón, Spain; NA, not available; SIDIAP, Information System for the Improve-
ment of Research in Primary Care, Catalonia, Spain; THIN, The Health Improvement Network, UK; UK, United Kingdom.
*Comorbidity was evaluated for any time before the start date.
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Sweden; 4.8%, GePaRD) and ischemic heart disease
(0.3%, EpiChron cohort; 7.0%, GePaRD).
DISCUSSION
In this study, we described the characteristics of
22 593 new users of cilostazol identiﬁed in the UK,
Spain, Sweden, and Germany. Prevalence of use
varied across study populations and countries, and it
was higher in Spain than in the other countries. Most
users were aged older than 60 years and had a high
prevalence of comorbidity, especially cardiovascular
disease and use of comedications. Concurrent use of
cilostazol and potent CYP3A4 and CYP2C19
inhibitors ranged from 3 to 22% of users. The baseline
assessment of labeling changes enabled estimation of
the potential impact that could be achieved after the
labeling changes were implemented in 2013. Up to
one third of users were current smokers when initiat-
ing treatment; most patients were monitored after the
start of treatment, up to 50% discontinued cilostazol
in the ﬁrst 3 months of therapy; and prevalence of
new contraindications and concurrent use of cilostazol
200 mg daily and potent CYP3A4 and CYP2C19
inhibitors was low. On-label prescribing of cilostazol
was variable, lower in Spain than in other countries,
and variability was probably related to the extent to
which diagnoses and free text were recorded in differ-
ent databases.
Published information on cilostazol use in general
practice is limited to a drug utilization study
conducted in Spain by Cantabrian regional health
service and the Spanish Medicines and Health
Products Agency12; the results are published only in
an abstract. The results from the EpiChron cohort
and SIDIAP (Spain) in our study are in line with
results from this study: Most cilostazol users were
elderly, with a high prevalence of comorbidity and
comedications, including those potentially interacting
with cilostazol, and did not achieve 6 months of treat-
ment. The high rates of discontinuation found in that
study and in our study could be driven not only by a
potential lack of effectiveness of cilostazol but also
by intolerance or adverse effects. Our study was not
designed to assess cause of discontinuation, and the
clinical information evaluated (e.g., reasons for
monitoring visits) did not provide further insight. In
a large randomized clinical trial, the most frequent
reasons for early termination were patient withdrawal
of consent (16%), adverse events (18%), and other
reasons (10%) (Hiatt et al., 2008). The high preva-
lence of comorbidity and concurrent use of multiple
medications, many interacting with cilostazol, could
also reduce the adherence to cilostazol treatment.
For example, the concurrent use of statins
Table 4. Percentage of new users of cilostazol with old contraindications
Contraindication*
THIN, UK
(n = 1528)
EpiChron Cohort,
Aragon, Spain
(n = 4024)
SIDIAP, Catalonia,
Spain (n = 10 142)
Sweden
(n = 2887)
GePaRD, Germany
(n = 4012)
% % % % %
Renal failure 2.4 NA 7.9 2.8 20.7
Liver disease 1.3 1.6 3.7 1.0 25.4
Heart failure 4.8 2.9 3.7 3.0 3.9
Risk factors for bleeding 1.8 1.7 29.9 5.7 16.3
Active peptic ulcer 0.1 0.1 0.1 0.4 3.9
Recent cerebral hemorrhage 0.0 NA 0.2 0.1 0.6
Proliferative diabetic retinopathy** 0.7 1.7 4.5 5.2 12.4
Poorly controlled hypertension*** 1.0 NA 26.6 NA NA
Arrhythmias 0.7 0.2 0.03 1.4 8.3
Ventricular tachycardia 0.1 0.2 0.02 0.6 1.5
Ventricular ﬁbrillation or multifocal ventricular ectopics 0.5 NA 0.01 0.8 7.3
Prolongation of the QT interval 0.0 NA NA 0.1 NA
Any contraindication 10.0 6.2 39.1 12.2 51.8
GePaRD, German Pharmacoepidemiological Research Database, Germany; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS),
Aragón, Spain; NA, not available; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health
Improvement Network, UK; UK, United Kingdom.
Note: Old contraindications refer to those already included in the labeling before the implementation of labeling changes in 2013.
*Contraindications were severe renal impairment, moderate-to-severe hepatic impairment, congestive heart failure, risk factors for bleeding (active peptic
ulcer, hemorrhagic stroke within the prior 6 months, proliferative diabetic retinopathy, and poorly controlled hypertension), and history of arrhythmias.
**Refers to diabetic retinopathy.
***Poorly controlled hypertension was evaluated in THIN by using speciﬁc Read codes and in SIDIAP deﬁned as any patient with a blood pressure value
greater than 140/90 mmHg or diagnosed with hypertension without at least one control of blood pressure recorded in the last 12 months. Blood pressure
values were not available in the rest of the study populations.
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(41.8–66.8% of new users) could precipitate or
aggravate leg pain, which could be attributed to
lack of efﬁcacy of cilostazol and lead to discontin-
uation of treatment.
A strength of our study is the use of automated health
databases, which typically capture information from
routine health care without modifying regular clinical
practice. This allowed identiﬁcation and characteriza-
tion of long-term baseline medication and comorbidity
history of a large number of cilostazol new users in
several European populations—all of Sweden and with
good representation of the overall country populations
for other countries. The availability of prescription and
dispensing records allowed a detailed evaluation of
coprescription patterns over long periods of time. A
limitation of the use of databases is the heterogeneity
of the data available for each population, which may
explain part of the variability of the prevalence of
comorbidity and contraindications (e.g., renal failure
and liver disease) in the different study populations.
The different health systems in each country or region
also contribute to the heterogeneity between databases.
Information recorded in THIN and GePaRD is based
on primary care, specialists, and hospital discharge
diagnoses. In the EpiChron cohort and SIDIAP,
information was restricted to primary care diagnoses
and in Sweden was limited to inpatient and outpatient
clinic hospital diagnoses.
Availability and speciﬁcity of some diagnoses used
to assess comorbidity and contraindications varied
between databases. Speciﬁc codes for renal failure
and cerebral hemorrhage were not available in the
EpiChron cohort. The diagnosis of proliferative
diabetic retinopathy was available in THIN only and
was approximated in the other databases by using the
broader term of diabetic retinopathy; poorly controlled
hypertension was evaluated in SIDIAP through
recorded values of blood pressure and in THIN
through Read codes. Also, to assess contraindications
associated with disease severity (e.g., moderate-to-
severe hepatic impairment), which is not captured in
the study databases, we used broad diagnostic terms
(e.g., liver disease) that could lead to misclassiﬁcation
and overestimation of the prevalence of these
conditions.
The completeness of recorded information may
differ between databases. Information on medications
can be considered complete in all databases as it is
based on the automatic recording of prescriptions
(THIN) or pharmacy dispensings (EpiChron cohort,
SIDIAP, Sweden, and GePaRD). However, a ﬁrst
specialist prescription may be missed in GP data-
bases (THIN and SIDIAP), which could overestimate
discontinuation of cilostazol. Also, relevant over-the-
counter medications, such as aspirin, are not recorded
in any of the study data sources. Information on
smoking was available in THIN and SIDIAP but
for only 48% of users in the EpiChron cohort.
Recording of diagnoses in THIN can be considered
reliable; estimates of the prevalence of chronic and
frequent disease are consistent with those reported
in national health statistics in the UK (Blak et al.,
2011). Recording of diagnoses for administrative
hospital requirements (Sweden) or for insurance
billing purposes (GePaRD) can also be considered
reasonably complete. The lower prevalence of
comorbidity in the EpiChron cohort than in SIDIAP
(e.g., diabetes, 29.9 vs. 40.4% respectively; hyperten-
sion, 54.9 vs. 63.0%; hyperlipidemia, 37.4 vs.
48.5%) could be related to some underrecording of
Table 6. Potential off-label prescribing of cilostazol
Diagnosis
THIN, UK
(n = 1528)*
EpiChron Cohort, Aragon,
Spain (n = 4024)
SIDIAP, Catalonia,
Spain (n = 10 142)*
Sweden
(n = 2887)
GePaRD, Germany
(n = 4012)
On-label prescribing 93.4% 53.6% 41.0% 70.2% 81.6%
Potential off-label prescribing 5.6% 7.9% 10.3% 24.5% 17.0%
Varices, phlebitis, and thrombophlebitis 0.0% 2.0% 2.1% 2.3% 3.9%
Leg and foot pain, symptoms, and complains 3.6% 1.5% 2.1% 1.3% 0%
Musculoskeletal disorders 0.0% 1.2% 0.0% 3.7% 4.6%
Cerebrovascular disease 1.0% 0.3% 2.1% 0.3% 4.8%
Ischemic heart disease 0.5% 0.3% 1.0% 0.6% 7.0%
Other cardiovascular disease 0.0% 1.6% 0.0% 16.2% 15.0%
Peripheral neuritis and neuropathy 1.0% 0.02% 0.0% 0.0% 0.0%
Other diagnoses/no diagnoses recorded 1.0% 38.5%** 48.7%*** 5.4% 1.5%
GePaRD, German Pharmacoepidemiological Research Database, Germany; GP, general practitioner; EpiChron, EpiChron cohort from Aragon Health Sci-
ences Institute (IACS), Aragón, Spain; SIDIAP, Information System for the Improvement of Research in Primary Care, Catalonia, Spain; THIN, The Health
Improvement Network, UK; UK, United Kingdom.
*Based on clinical review of patient proﬁles and free text of a random sample of users.
**A total of 1541 patients (38.3%) had other diagnoses, and 11 (0.3%) did not have any recorded diagnosis.
***A total of 14 patients (7.2%) had other diagnoses, and 81 (41.5%) did not have any recorded diagnosis.
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diagnoses in the EpiChron cohort. Conversely, the
lower percentages of patients in the EpiChron cohort
treated with antihypertensives (63.6 vs. 74.5%,
SIDIAP), blood glucose-lowering drugs (20.9 vs.
32.2%), and insulin (11.8 vs. 15.5%) suggest that
these differences could be due to different character-
istics of cilostazol users (e.g., more severe patients in
SIDIAP) or to different patterns of use of health ser-
vices, which are organized and managed at the re-
gional level.
The frequency of on-label prescribing of cilostazol
varied between the study databases and was lower
in Spain than in the other countries. This variability
could reﬂect not only differences in the recording of
diagnoses between databases but also differences in
the prescribing patterns of each country or region.
Evaluation of off-label use was based on the
absence of recorded diagnoses for intermittent
claudication or peripheral arterial disease. Thus, the
absence of recorded information does not exclude
that the diagnosis may have occurred but may not
have been recorded. This may have led to
overestimating off-label prescribing in these
populations.
CONCLUSIONS
This study indicates that the prevalence of cilostazol
use varied by country and was higher in Spain than
in the UK, Sweden, and Germany, and in men than
in women. Among cilostazol users, the high preva-
lences of risk factors, comorbidity, and concurrent
use of medications including interacting drugs sug-
gest that this is a vulnerable population at increased
risk of complications and especially cardiovascular
events.
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• The study evaluated the characteristics of 22 593
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